Kura Oncology

cancer target detection radiopharma radio
Biotech

ASCO: Kura, Kyowa reveal 23% remission rate behind leukemia win

Kura and Kyowa Kirin have shared details of the phase 2 win for ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor.
James Waldron Jun 2, 2025 5:36pm
cancer target detection radiopharma radio

Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data

Feb 6, 2025 10:40am
parachute snow mountains

Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders

Jan 10, 2025 8:30am
pay deal hand over cash licensing transaction money

Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug

Nov 21, 2024 9:35am
Graphic of a drop of blood made up of small data points and nodes

Kura's leukemia drug works best when tacked onto existing combo

Jan 30, 2024 11:15am
visual of money going into a piggy bank

Kura pulls up to $150M from Bristol Myers, VC Hercules loan

Nov 3, 2022 11:20am